Nuvalent (NUVL) is up 15.8%, or $15.29 to $111.79.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $135 from $115 at Stifel
- Nuvalent price target raised to $149 from $140 at Leerink
- Nuvalent’s Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path
- Nuvalent’s Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans
- Nuvalent price target raised to $155 from $130 at H.C. Wainwright